JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy

Jak inhibitors are potent anti-inflammatory drugs that have the potential to dampen the hyperactive inflammatory response associated with severe COVID-19. We reviewed the clinical outcomes of 218 patients with COVID-19 hospitalized for severe pneumonia and treated with ruxolitinib through a compassi...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical medicine Vol. 10; no. 16; p. 3752
Main Authors:	Vannucchi, Alessandro Maria, Mortara, Andrea, D’Alessio, Andrea, Morelli, Mara, Tedeschi, Alberto, Festuccia, Moreno Benedetto, Monforte, Antonella D’Arminio, Capochiani, Enrico, Selleri, Carmine, Simonetti, Federico, Saracino, Annalisa, Rapezzi, Davide, Badagliacca, Maria Rita, Falasca, Katia, Molteni, Alfredo, Palazzolo, Roberto, Schettino, Giuliano, Bocchia, Monica, Turrini, Mauro, Ascierto, Paolo A., Zuurman, Mike, Paley, Carole, Coco, Paola, Saglio, Giuseppe
Format:	Journal Article
Language:	English
Published:	Basel MDPI AG 23-08-2021 MDPI
Subjects:	Clinical medicine Coronaviruses COVID-19 Cytokines Data collection Graft versus host disease Infections Inflammation Laboratories Lymphocytes Mortality Patients Pneumonia Severe acute respiratory syndrome coronavirus 2 Steroids
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Jak inhibitors are potent anti-inflammatory drugs that have the potential to dampen the hyperactive inflammatory response associated with severe COVID-19. We reviewed the clinical outcomes of 218 patients with COVID-19 hospitalized for severe pneumonia and treated with ruxolitinib through a compassionate use program. Data on the duration of treatment; outcomes at 4, 7, 14, and 28 days; oxygen support requirements; clinical status; and laboratory parameters were retrospectively collected. Overall, according to the physician evaluation, 66.5% of patients showed improvement at follow-up; of these, 83.5% showed improvement by day 7. Oxygen support status also showed improvement, and by day 7, 21.6% of patients were on ambient air, compared with 1.4% at baseline, which increased to 48.2% by day 28. Significant decreases in C-reactive protein and increases in the lymphocyte total count were already observed by day 4, which seemed to correlate with a positive outcome. At the end of the observation period, 87.2% of patients were alive. No unexpected safety findings were observed, and grade 3/4 adverse events were reported in 6.9% of patients.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	2077-0383 2077-0383
DOI:	10.3390/jcm10163752